Recruiting studies: Histiocytic Neoplasm

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924 Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Phase 1 · 31 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05476770 This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Phase 1 · 6 location(s) · LTZ Therapeutics, Inc. · NCT07121946 Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL
Phase N/A · 1 location(s) · Ain Shams University · NCT07057765 A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820 Histiocytic Disorder Follow-up Study
Phase N/A · 1 location(s) · University of Alabama at Birmingham · NCT05915208 A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06736613 Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810 Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy
Phase N/A · 1 location(s) · Incyte Biosciences Italy S.r.l · NCT06299553 DALY II Japan/MB-CART2019.1 for DLBCL
Phase 2 · 5 location(s) · Miltenyi Biomedicine GmbH · NCT07288879 Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
Phase 2 · 1 location(s) · Zhejiang Provincial People's Hospital · NCT06534762 Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06151080 Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL
Phase 2 · 7 location(s) · University Medical Center Groningen · NCT05641428 International Rare Histiocytic Disorders Registry (IRHDR)
Phase N/A · 15 location(s) · The Hospital for Sick Children · NCT02285582 Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT06980116 Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555 CAR-T Followed by Bispecific Antibodies
Phase 2 · 2 location(s) · Abramson Cancer Center at Penn Medicine · NCT04889716 Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Phase 1 · 1 location(s) · Florida International University · NCT05857969 Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06891157 Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Phase 2 · 12 location(s) · Carl Allen · NCT04079179 Ulixertinib in People With Histiocytic Neoplasms
Phase 2 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT06411821 Real-World Study of DLBCL With Different Genetic Subtypes
Phase N/A · 1 location(s) · Ruijin Hospital · NCT06026488 Glofitamab in Chinese Patients With R/R DLBCL
Phase N/A · 1 location(s) · Peking Union Medical College Hospital · NCT06481826 CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial
EARLY_Phase 1 · 1 location(s) · Institute of Hematology and Blood Transfusion, Czech Republi · NCT06765876 Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
Phase N/A · 5 location(s) · Pell Bio-Med Technology Co., Ltd. · NCT05377307 Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers
Phase 2 · 10 location(s) · Fred Hutchinson Cancer Center · NCT03779854 HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Ste
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03326921 In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
EARLY_Phase 1 · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT05093335 Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Phase 2 · 1 location(s) · Virginia Commonwealth University · NCT06846463 CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
Phase 1 · 2 location(s) · St. Jude Children's Research Hospital · NCT04318678

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.